These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 19576489)

  • 1. [Mechanisms of action of botulinum toxins and neurotoxins].
    Poulain B; Lonchamp E; Jover E; Popoff MR; Molgó J
    Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S73-6. PubMed ID: 19576489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mode of action of botulinum neurotoxin: pathological, cellular and molecular aspect].
    Poulain B; Humeau Y
    Ann Readapt Med Phys; 2003 Jul; 46(6):265-75. PubMed ID: 12928128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular mechanism of action of tetanus toxin and botulinum neurotoxins].
    Poulain B
    Pathol Biol (Paris); 1994 Feb; 42(2):173-82. PubMed ID: 7916455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clues to the multi-phasic inhibitory action of botulinum neurotoxins on release of transmitters.
    Dolly JO; Ashton AC; McInnes C; Wadsworth JD; Poulain B; Tauc L; Shone CC; Melling J
    J Physiol (Paris); 1990; 84(3):237-46. PubMed ID: 1963641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clostridium botulinum and botulinum neurotoxin].
    Hirai Y
    Brain Nerve; 2011 Jul; 63(7):755-61. PubMed ID: 21747146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25.
    Blasi J; Chapman ER; Link E; Binz T; Yamasaki S; De Camilli P; Südhof TC; Niemann H; Jahn R
    Nature; 1993 Sep; 365(6442):160-3. PubMed ID: 8103915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.
    Arndt JW; Chai Q; Christian T; Stevens RC
    Biochemistry; 2006 Mar; 45(10):3255-62. PubMed ID: 16519520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How botulinum and tetanus neurotoxins block neurotransmitter release.
    Humeau Y; Doussau F; Grant NJ; Poulain B
    Biochimie; 2000 May; 82(5):427-46. PubMed ID: 10865130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Botulinum neurotoxin].
    Poulain B
    Rev Neurol (Paris); 2010 Jan; 166(1):7-20. PubMed ID: 19846187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of synaptic neurotransmitter release mechanisms using bacterial toxins].
    Doussau F; Humeau Y; Vitiello F; Popoff MR; Poulain B
    J Soc Biol; 1999; 193(6):457-67. PubMed ID: 10783704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity.
    Rummel A
    Curr Top Microbiol Immunol; 2013; 364():61-90. PubMed ID: 23239349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the light chain subcellular localization an important factor in botulinum toxin duration of action?
    Fernández-Salas E; Ho H; Garay P; Steward LE; Aoki KR
    Mov Disord; 2004 Mar; 19 Suppl 8():S23-34. PubMed ID: 15027051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability.
    Baldwin MR; Bradshaw M; Johnson EA; Barbieri JT
    Protein Expr Purif; 2004 Sep; 37(1):187-95. PubMed ID: 15294297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of botulinum neurotoxin serotypes a and B with synaptic vesicle protein complexes.
    Baldwin MR; Barbieri JT
    Biochemistry; 2007 Mar; 46(11):3200-10. PubMed ID: 17311420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of neurotransmitter release by botulinum neurotoxins and tetanus toxin at Aplysia synapses: role of the constituent chains.
    Poulain B; Mochida S; Wadsworth JD; Weller U; Habermann E; Dolly JO; Tauc L
    J Physiol (Paris); 1990; 84(4):247-61. PubMed ID: 1981913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial neurotoxins--a thousand years later.
    Linial M
    Isr J Med Sci; 1995 Oct; 31(10):591-5. PubMed ID: 7591680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity-dependent changes in partial VAMP complexes during neurotransmitter release.
    Hua SY; Charlton MP
    Nat Neurosci; 1999 Dec; 2(12):1078-83. PubMed ID: 10570484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators.
    Dolly JO; Wang J; Zurawski TH; Meng J
    FEBS J; 2011 Dec; 278(23):4454-66. PubMed ID: 21645262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity.
    Schmidt JJ; Stafford RG
    Biochemistry; 2005 Mar; 44(10):4067-73. PubMed ID: 15751983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity.
    Jin R; Rummel A; Binz T; Brunger AT
    Nature; 2006 Dec; 444(7122):1092-5. PubMed ID: 17167421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.